drug · small molecule
QULIPTA
updated 5mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.
targets
Calcitonin gene-related peptide type 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying QULIPTA
- phase3A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- phase3A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- —Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
- phase3Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
- phase3Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
- phase3Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- phase3A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
News(1)
- New guidelines on migraine prevention reflect increasing options for patients“There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.stat · 29d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that